Drug Trial Radar · NCT06546995
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Jul 9, 2024
Primary completion
Nov 19, 2025
Study completion Nov 19, 2025
Sponsor
- Lead sponsor
- Neumora Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly. Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease. Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment. Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.
Conditions
- Alzheimer's Disease
- Healthy Elderly
Interventions
NMRA-323511Drug
Participants will receive NMRA-323511 orally.
PlaceboDrug
Participants will receive matching placebo tablets orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Tolerability Assessments Based on Treatment Emergent Adverse Events (TEAEs) and Validated Clinical ScalesTime frame: Up to 53 days
- Part B: Safety and Tolerability Assessments Based on Treatment Emergent Adverse Events and Validated Clinical ScalesTime frame: Up to Week 10
- Part B: Change from Baseline to Week 8 on the Cohen-Mansfield Agitation Inventory (CMAI) Total ScoreTime frame: Baseline to Week 8
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Neumora Investigator Site
Chandler, Arizona
Neumora Investigator Site
Tempe, Arizona
Neumora Investigator Site
Costa Mesa, California
Neumora Investigator Site
Lomita, California
Neumora Investigator Site
Walnut Creek, California
Neumora Investigator Site
Bradenton, Florida
Neumora Investigator Site
Greenacres City, Florida
Neumora Investigator Site
Hallandale, Florida
Neumora Investigator Site
Hialeah, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator Site
Miami, Florida
Neumora Investigator Site
Miami Springs, Florida
Neumora Investigator Site
Orlando, Florida
Neumora Investigator Site
Pembroke Pines, Florida
Neumora Investigator Site
Port Orange, Florida
Neumora Investigator Site
Atlanta, Georgia
Neumora Investigator Site
Honolulu, Hawaii
Neumora Investigator Site
Boise, Idaho
Neumora Investigator Site
Belmont, Massachusetts
Neumora Investigator Site
Troy, Michigan
Neumora Investigator Site
Toms River, New Jersey
Neumora Investigator Site
Brooklyn, New York
Neumora Investigator Site
East Syracuse, New York
Neumora Investigator Site
Charlotte, North Carolina
Neumora Investigator Site
Mesquite, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.